Newsroom

Page Meta: of 97 press releases

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Reports Second Quarter 2022 Financial Results and Business Highlights

Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

For all media enquiries please get in touch

media@freeline.life